Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 46 of 752 for:    Anti-Infective Agents AND Antibiotics, Antitubercular AND culture

Detection of Bloodstream Pathogens in Hematological Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03896880
Recruitment Status : Not yet recruiting
First Posted : April 1, 2019
Last Update Posted : June 19, 2019
Sponsor:
Information provided by (Responsible Party):
Marwa Mohammed Tolba, Assiut University

Brief Summary:
  • To identify the common bacterial and fungal species causing fungemia and bacteremia in hematological malignancies.
  • To identify sensitivity pattern for causative microbes.
  • Compare culture on ordinary media with Vitek2 (automated microbial identification system) and multiplex polymerase chain reaction (PCR )

Condition or disease Intervention/treatment
Bloodstream Infection Diagnostic Test: blood culture Other: Anti fungal susceptibility testing or antibiotic susceptibility testing Other: phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France) Other: Identification of the isolated organism by multiplex PCR

Detailed Description:
Sepsis is a global health problem and an estimated 17 million cases of sepsis occur each year in the world .The early initiation of appropriate antibiotic therapy is determinant for the prognosis and survival of patients with bloodstream infections . Infections in patients suffering from hematological malignancies are a frequent problem, leading to higher mortality and morbidity, increased costs of health care and prolonged duration of hospitalization. Common among these infections are those involving the bloodstream. In febrile neutropenic patients, the attack rate of bloodstream infection was reported to be between 11 and 38% . Hematological malignancies by themselves or by their therapeutic strategies, put patients at risk for infections. Wide use of antibiotics and prophylactic agents in such patients has led to the development of resistance. The general term fungemia describes the presence of a fungal species in the blood while term bacteremia describes the presence of bacterial species in the blood A positive culture may indicate a widespread infection or commonly, the infection of an intravenous catheter .Fungal microbes are abundant in nature and are frequent colonizers on human mucosal surfaces. However, under conditions of impaired immune responses or a break in host barriers, fungi are able to invade normally sterile areas of the human body, where they can cause severe infections that are difficult to recognize and treat and are often ultimately lethal .Indeed, recent epidemiological data show that invasive fungal infections (IFIs) are frequently encountered in clinical practice, with the most common offenders, being Candida spp. and Aspergillus spp. In order to effectively eliminate these infections, early diagnosis and species identification are of paramount importance. Traditional diagnostic methods such as blood culture is still considered the gold standard .Indeed ,novel molecular and non molecular techniques have been developed and currently under clinical evaluation . The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods. The application of the multiplex polymerase chain reaction PCR method in the diagnosis of bloodstream infections is designed to reduce the time for identification of the microorganisms grown from the positive samples to 24-48 hours, as pathogens are identified directly from a positive blood sample

Layout table for study information
Study Type : Observational
Estimated Enrollment : 139 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Detection of Bloodstream Pathogens in Hematological Malignancies
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : September 1, 2020
Estimated Study Completion Date : December 2020

Group/Cohort Intervention/treatment
blood culture positive
hematological malignancy patients with positive blood culture
Diagnostic Test: blood culture

During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).

A-Identification of microorganisms including:

  1. Isolation of microorganisms:
  2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.

B-Identification of the bacterial organism

Pure colonies of isolated microorganisms were identified by:

Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests

C-For fungi isolate the following will perform:

  1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.
  2. Culture on Brilliance Candida differential agar

Other: Anti fungal susceptibility testing or antibiotic susceptibility testing
isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
Other Name: antimicrobial susceptibility testing

Other: phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)
The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
Other Name: Vitek2 (BioMerieux,France)

Other: Identification of the isolated organism by multiplex PCR
FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
Other Names:
  • FilmArray blood culture identification (BCID)
  • multiplex PCR




Primary Outcome Measures :
  1. identify pathogens in positive blood culture in hematological malignancies patients [ Time Frame: 1 year ]
    Examine blood culture to diagnose different species of pathogens including bacteria and fungi responsible for bloodstream infection in hematological malignancies patients.

  2. Antimicrobial susceptibility testing and drug resistance [ Time Frame: 1 year ]
    performance of antimicrobial susceptibility testing (anti fungal susceptibility testing or antibiotic susceptibility testing )of significant bacterial isolates. The goals of testing are to detect possible drug resistance in common pathogens and to assure susceptibility to drugs of choice for particular infections.

  3. prevalence of bloodstream infection in hematological malignancy patients [ Time Frame: 1 year ]
    prevalence of both bacteremia and fungemia in hematological malignancies using blood culture

  4. Time from blood collection to pathogen identification [ Time Frame: 1 year ]
    The hypothesis is that faster identification will lead to faster action.


Secondary Outcome Measures :
  1. In-hospital mortality. [ Time Frame: 1 year ]
    Faster treatment is associated with reduced mortality

  2. Rapid diagnosis of bloodstream infections [ Time Frame: 1 year ]
    Compare different methods for rapid identification of blood culture positive results including Vitek2 (BioMerieux,France) and multiplex PCR



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
hematological malignancy patients with fever
Criteria

Inclusion Criteria:

  • hematological malignancy patients on chemotherapy associated with fever

Exclusion Criteria:

  • Age below 18 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03896880


Contacts
Layout table for location contacts
Contact: Marwa M mohammed, ass.lecture +201013608146 marwa.mohammed.tolba.1989@gmail.com
Contact: Amal M Hosni, lecturer +201026122444 amal.alameldin@yahoo.com

Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Study Director: Mohamed Z Abo krisha, professor Assiut University

Publications:
Layout table for additonal information
Responsible Party: Marwa Mohammed Tolba, Principle investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03896880     History of Changes
Other Study ID Numbers: Cancer bloodstream infection
First Posted: April 1, 2019    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Antibiotics, Antitubercular
Antifungal Agents
Anti-Infective Agents
Antitubercular Agents
Physiological Effects of Drugs
Neoplasms
Miconazole
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP3A Inhibitors